Alumis (ALMS) Competitors $4.13 -0.01 (-0.24%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.16 +0.04 (+0.85%) As of 08/1/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ALMS vs. QURE, SION, SNDX, DNA, CRMD, ANAB, VIR, XERS, CRON, and IMTXShould you be buying Alumis stock or one of its competitors? The main competitors of Alumis include uniQure (QURE), Sionna Therapeutics (SION), Syndax Pharmaceuticals (SNDX), Ginkgo Bioworks (DNA), CorMedix (CRMD), AnaptysBio (ANAB), Vir Biotechnology (VIR), Xeris Biopharma (XERS), Cronos Group (CRON), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. Alumis vs. Its Competitors uniQure Sionna Therapeutics Syndax Pharmaceuticals Ginkgo Bioworks CorMedix AnaptysBio Vir Biotechnology Xeris Biopharma Cronos Group Immatics Alumis (NASDAQ:ALMS) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk. Do insiders and institutionals have more ownership in ALMS or QURE? 78.8% of uniQure shares are owned by institutional investors. 40.7% of Alumis shares are owned by insiders. Comparatively, 4.8% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, ALMS or QURE? uniQure has higher revenue and earnings than Alumis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumisN/AN/A-$294.23MN/AN/AuniQure$27.12M27.70-$239.56M-$3.92-3.49 Do analysts rate ALMS or QURE? Alumis presently has a consensus target price of $19.80, suggesting a potential upside of 379.42%. uniQure has a consensus target price of $36.55, suggesting a potential upside of 166.95%. Given Alumis' stronger consensus rating and higher possible upside, analysts plainly believe Alumis is more favorable than uniQure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14uniQure 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.91 Is ALMS or QURE more profitable? Alumis has a net margin of 0.00% compared to uniQure's net margin of -1,387.98%. Alumis' return on equity of -406.27% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets AlumisN/A -406.27% -107.29% uniQure -1,387.98%-1,010.74%-33.27% Which has more risk and volatility, ALMS or QURE? Alumis has a beta of -1.5, meaning that its share price is 250% less volatile than the S&P 500. Comparatively, uniQure has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Does the media prefer ALMS or QURE? In the previous week, uniQure had 19 more articles in the media than Alumis. MarketBeat recorded 24 mentions for uniQure and 5 mentions for Alumis. Alumis' average media sentiment score of 0.34 beat uniQure's score of 0.22 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral uniQure 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryuniQure beats Alumis on 7 of the 13 factors compared between the two stocks. Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALMS vs. The Competition Export to ExcelMetricAlumisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$225.24M$3.00B$5.48B$9.52BDividend YieldN/A2.43%4.73%4.08%P/E RatioN/A17.6228.6723.80Price / SalesN/A178.97373.5466.64Price / CashN/A41.9535.4557.96Price / Book0.758.508.275.55Net Income-$294.23M-$55.06M$3.24B$259.03M7 Day Performance6.44%-3.98%-3.69%-4.59%1 Month Performance25.91%9.59%4.33%4.46%1 Year Performance-68.18%6.72%25.95%18.03% Alumis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALMSAlumis3.0993 of 5 stars$4.13-0.2%$19.80+379.4%-67.5%$225.24MN/A0.00N/AQUREuniQure2.4186 of 5 stars$15.210.0%$37.82+148.7%+83.0%$832.60M$20.20M-3.46500Trending NewsEarnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionSIONSionna TherapeuticsN/A$18.74-2.1%$38.50+105.4%N/A$826.88MN/A0.0035Positive NewsLockup ExpirationSNDXSyndax Pharmaceuticals3.5579 of 5 stars$9.56-4.3%$34.10+256.6%-54.6%$826.48M$43.72M-2.49110Upcoming EarningsDNAGinkgo Bioworks1.1775 of 5 stars$14.03-5.9%$8.50-39.4%N/A$820.47M$227.04M-1.53640News CoverageGap DownCRMDCorMedix2.6643 of 5 stars$11.59+0.7%$17.14+48.0%+161.0%$791.46M$43.47M53.0530News CoveragePositive NewsANABAnaptysBio2.2241 of 5 stars$26.93-0.2%$47.13+75.0%-27.6%$791.06M$111.87M-5.55100News CoveragePositive NewsUpcoming EarningsVIRVir Biotechnology2.8932 of 5 stars$5.71-1.0%$30.25+430.2%-48.3%$790.04M$74.21M-1.35580News CoverageUpcoming EarningsShort Interest ↑XERSXeris Biopharma3.383 of 5 stars$5.03-2.8%$6.25+24.4%+121.4%$785.84M$222.55M-16.75290News CoveragePositive NewsUpcoming EarningsShort Interest ↑CRONCronos Group2.3154 of 5 stars$2.04-1.7%N/A-17.0%$784.86M$117.61M15.66450Upcoming EarningsIMTXImmatics2.1547 of 5 stars$6.44-0.2%$14.67+127.7%-45.1%$784.00M$168.65M-37.94260 Related Companies and Tools Related Companies QURE Alternatives SION Alternatives SNDX Alternatives DNA Alternatives CRMD Alternatives ANAB Alternatives VIR Alternatives XERS Alternatives CRON Alternatives IMTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALMS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALMS Stock Alerts